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PAMAM Dendrimers as a Carbamazepine Delivery System for Neurodegenerative Diseases: 
A Biophysical and Nanotoxicological Characterization 
 
Abstract 
Carbamazepine (CBZ) is an antiepileptic drug, which also could be used in the treatment of 
neurodegenerative diseases, such as the Alzheimer's disease. However, its use has been limited due to its 
low solubility, inefficient pharmacokinetic profiles, and multiple side effects. PAMAM dendrimers, 
ethylenediamine core, generation 4.0 (amine terminal groups) and 4.5 (carboxylate terminal groups) 
(DG4.0 and DG4.5 respectively) are polymers that can increase drug solubility through complexation. Thus, 
the aim of this work was to obtain and characterize complexes between CBZ and dendrimers. Both DG4.0 
and DG4.5 allowed the incorporation of ~20 molecules of CBZ per dendrimer, into their hydrophobic 
pockets. DG4.0-CBZ and DG4.5-CBZ complexes were found to be stable for 90 days at 37 °C and resistant 
to a lyophilization process, presenting controlled drug release. Also, the complexes nanotoxicity was tested 
ex vivo (human red blood cells), in vitro (N2a cell line), and in vivo (zebrafish). No hemolytic effect was 
observed in the ex vivo model. As regards in vitro toxicity, the DG4.5-CBZ complexes significantly reduced 
the toxicity caused by the free drug. Moreover, the DG4.5-CBZ did not cause neurotoxicity or cardiotoxicity 
in zebrafish larvae. In conclusion, a stable and biocompatible drug delivery system based on the DG4.5 
capable of complex the CBZ has been developed. This achievement highlights the advantages of using 
negatively charged dendrimers for nanomedicine.  
 
Keywords: Carbamazepine, PAMAM dendrimers, Complexation, Toxicology, Neurodegenerative disease, 
Epilepsy.  
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Highlights  
 The PAMAM dendrimers generation 4.0 and 4.5 (DG4.0 and DG4.5) encapsulated around of 20 
molecules of carbamazepine (CBZ) per molecule of dendrimer, tripling the solubility of the drug. 
 The DG4.0-CBZ and DG4.5-CBZ complexes were stable for 90 days stored at 37 °C and resistant 
to a lyophilization process.  
 Both DG4.0-CBZ and DG4.5-CBZ complexes showed a controlled release of the CBZ under 
physiological conditions, retaining 40% of the drug after 24 h of dialysis. The interaction between 
CBZ and dendrimers occurs in their hydrophobic pockets. 
 The DG4.0-CBZ and DG4.5-CBZ complexes did not show hemolytic effects. The DG4.5-CBZ 
complexes reduced the cytotoxicity caused by the free drug in cell culture. The DG4.5-CBZ 
complexes were biocompatible according to the tests carried out on zebrafish larvae. 
 A stable and biocompatible drug delivery system based on the DG4.5 capable of efficiently complex 
the CBZ has been developed. 
 
Abbreviations 
BBB: blood-brain barrier; CBZ: Carbamazepine; CV: crystal violet; DDS: drug delivery system; DG4.0: 
polyamidoamine dendrimer generation 4.0; DG4.5: polyamidoamine dendrimer generation 4.5; DMSO: 
dimethylsulfoxide; dpf: days post-fecundation; FBS: fetal bovine serum; FTIR: Fourier Transform Infrared 
Spectroscopy; hpf: hours post-fecundation; hpi: hours post-incubation; MEM: minimum essential medium; MTT: 3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide; NR: neutral red; PAMAM: polyamidoamine; PBS: 
phosphate buffer saline.
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1. Introduction 
The protein misfolding and abnormal aggregation of specific proteins are involved in the most prevalent 
neurodegenerative disorders, including Alzheimer´s disease, amyotrophic lateral sclerosis, Parkinson´s 
disease, and Huntington´s disease (Guo et al., 2017). The generation of highly diffusible small oligomers, 
fibrils and large aggregates with amyloid properties are implicated in these abnormal processes (Vidal et 
al., 2014). Lately, due to the selective degradation of abnormally folded protein by the lysosomal pathway 
and the disruption of aggregated proteins, the enhancers of natural autophagy process have become 
attractive as a treatment for these neurodegenerative disorders (Budini et al., 2017; Harris & Rubinsztein, 
2012; Hidvegi et al., 2010; Vidal et al., 2014).  
More recently, it has been found that carbamazepine (CBZ), an FDA approved anticonvulsant and mood-
stabilizing drug has a potent autophagy enhancement effect (Harris & Rubinsztein, 2012; Hidvegi et al., 
2010) which reduces the accumulation and toxic effects of aggregation-prone proteins in in vitro cell models 
and protects against neurodegeneration in vivo (Li et al., 2013; Williams et al., 2008; L. Zhang et al., 2017). 
CBZ is traditionally given as a solid dosage or suspensions form by oral administration, but due to its poor 
solubility in water (120 µg/mL, 500 µM, at 25 °C) (Brewster et al., 1990; Hemenway et al., 2009; Martins et 
al., 2012), it has a slow and irregular gastrointestinal absorption, leading to an incomplete drug 
bioavailability (El-Zein et al., 1998; Gavini et al., 2006; Kobayashi et al., 2000). In addition, this reduced 
solubility does not allow its incorporation in therapeutic dosages in aqueous solutions for intravenous 
injection (Serralheiro et al., 2014). Also, the CBZ pharmacokinetic is complex because there is no direct 
relationship between the given oral dose and the concentration of the drug found in plasma (Alrashood, 
2016; Jiao et al., 2003). Therefore, it is necessary to use a high oral dose (800-1200 mg/day) to achieve 
the therapeutic concentration of CBZ, which has been estimated at 0.004-0.012 mg/mL (Kong et al., 2014). 
Furthermore, CBZ undergoes extensive hepatic metabolism and enzymatic induction that outcome in 
erratic plasmatic fluctuations and unexpected clearance increments, which demand successive dose 
adjustments (Serralheiro et al., 2014; Tomson et al., 1987; Yuen et al., 2008). 
Taking into account the above considerations, improving the solubility of CBZ may increase the rate of 
absorption, enhance the oral bioavailability and allow reducing the oral dose needed to accomplish 
therapeutic concentrations. Therefore, CBZ is a promising candidate to be used into a drug delivery system 
(DDS) with controlled release properties for the treatment of neurodegenerative diseases. A DDS delivers a 
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drug to a predetermined specific site (target organ/tissue) and, in this way, they allow to reduce the side 
effects by decreasing access to other tissues or organs where they do not have the therapeutic effect 
(Kakkar et al., 2017). The brain is an essential organ from which most of the vital functions are controlled. It 
is isolated and protected from the external environment by the blood-brain barrier (BBB). The same 
mechanisms that prevent the entry of harmful foreign substances avoid the access of therapeutic drugs. 
Hence, it is important to design DDSs that are capable of massively direct the drug to the brain, especially 
in the treatment of neurodegenerative diseases (Saraiva et al., 2016). 
The dendrimers are three-dimensional polymers obtained by organic synthesis that provide unique 
properties to the DDS field, since they have relevant characteristics such as minimal polydispersity, defined 
surface structure with globular shape, high water solubility, and very small and controlled size in the range 
of nanometers (Kalomiraki et al., 2016; Kesharwani et al., 2014; Svenson & Tomalia, 2012; Tomalia et al., 
1990). Generation 4.0 and 4.5 PAMAM dendrimers are optimal as DDS since they can incorporate drug 
molecules into their hydrophobic pockets, which are size- and shape-controlled, or anchor them to their 
surface groups by ionic or covalent interactions (Markowicz-Piasecka & Mikiciuk-Olasik, 2016). Thus, the 
complexed drug would acquire the physicochemical properties of the dendrimers, which would significantly 
increase its solubility in aqueous media and, therefore, modify its pharmacokinetics and biodistribution 
properties. In previous works, our group demonstrated that the drugs sulfadiazine and risperidone 
complexed with PAMAM dendrimers increment their solubility in water and the arrival to the brain, 
generating an increase in the potency of their effect (M. Prieto et al., 2006; M. Prieto et al., 2008; Maria 
Jimena Prieto et al., 2013; Maria Jimena Prieto et al., 2014; María Jimena Prieto et al., 2011). 
For those mentioned above, the present study aims to develop and characterize a novel drug delivery 
system for CBZ based on PAMAM dendrimers for the treatment of neurodegenerative disorders. This 
strategy is focused on increasing CBZ solubility, decreasing the dose and frequency of administration 
reducing side effects and probably improving the cost-effective balance of the therapy.  
 
 
2. Materials and Methods  
 
2.1. Materials 
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Polyamidoamine (PAMAM) dendrimers (D), with ethylenediamine core, generation 4.0 (mol weight = 
14,214 g/mol, 64 amine terminal groups) (DG4.0) and PAMAM dendrimers generation 4.5 (mol weight = 
26,251 g/mol, 128 carboxylate terminal groups) (DG4.5) were purchased from SIGMA-ALDRICH (MERCK, 
Argentina) and were used without further purification. Carbamazepine (CBZ), 5H-dibenzo[b,f]azepine-5-
carboxamide (mol weight = 236.27 g/mol), was generously donated by Ph.D. Albertina Moglioni from the 
Chemistry and Drug Metabolism Institute (IQUIMEFA-CONICET) (Buenos Aires, Argentina). Sodium 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide (MTT) was from USB Corporation, cell culture MEM 
was from HyClone, and antibiotic-antimycotic solution and trypsin were from Gibco, all purchased from 
Thermo Fisher Scientific, Argentina. Fetal bovine serum was from Internegocios S.A., Argentina. Crystal 
violet was from Sigma-Aldrich (MERCK, Argentina) and Neutral red was from BioPack (Argentina). All other 
reagents were of analytical grade and used without further purification.  
 
2.2. CBZ complexation in DG4.0 and DG4.5 
Different amounts of CBZ were combined with a constant amount of DG4.0 or DG4.5 in methanolic solution 
to obtain different D:CBZ molar ratios (1:5, 1:10, 1:25, 1:50, 1:100, 1:150 and 1:200); corresponding to 
0.024 mM of dendrimers and 0.12, 0.24, 0.6, 1.2, 2.4, 3.6 or 4.8 mM of CBZ, respectively. The mixtures 
were incubated for 24 h at 28 °C and, then, methanol was evaporated at 25 °C in a SAVANT TM SpeedVac 
Concentrator (Thermo Fisher Scientific, USA). The solid residues obtained were dissolved in 0.1 mL of 
phosphate buffer saline (PBS 10 mM, pH=7.4) at room temperature and centrifuged at 10,000×g for 5 min, 
to separate the D-CBZ complexes from the non-soluble unincorporated CBZ (Figure S1).  
 
2.3. Drug quantification by UV-Vis spectroscopy 
NanoDrop 1000 UV-Vis spectrometer (Thermo Fisher Scientific, USA) was used to quantify the amount of 
CBZ incorporated in the dendrimer. In PBS (10 mM, pH=7.4), CBZ has its maximum absorbance at ʎmax= 
284 nm. The stock solution of CBZ was obtained in a solution of 10% (v/v) ethanol in PBS. A calibration 
curve of CBZ at different concentrations in PBS was set determining the absorbance at this wavelength. 
The calibration curve was linear in a concentration range of 0.41–211 µM (R2=0.9994). The D-CBZ 
complexes were dissolved in PBS. Since dendrimers have no absorbance at this wavelength, the 
absorbance obtained from D-CBZ complexes can be attributed to CBZ (Figure S2). The obtained 
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absorbance was correlated with the calibration curve, and the amount of CBZ was determined. The total 
amount of CBZ in the D-CBZ complexes corresponds to both the soluble unincorporated CBZ and the 
complexed CBZ. The amount of CBZ present in a free CBZ control (performed in the same buffer and 
conditions) was subtracted from the total amount of CBZ determined for the D-CBZ complexes to calculate 
the quantity of the complexed CBZ. Since the concentration of dendrimer was known, the results were 
expressed as the number of moles of CBZ incorporated per mole of dendrimer. 
 
2.4. D-CBZ complexes stability and resistance to lyophilization process  
The time stability of free or complexed CBZ was studied after storage at 4, 25 or 37 °C. The amount of CBZ 
in the suspensions after 1, 7, 14, 21, 28, 35, and 90 days post-complexation were measured as described 
in Section 2.3. The soluble CBZ present in the control of free drug was used to set the 100% and all sample 
data was adjusted to this value. Also, the stability of the complexes after the lyophilization process was 
studied. Lyophilization was performed from frozen suspensions (-80 °C overnight) of CBZ, DG4.0-CBZ and 
DG4.5-CBZ without additives, in a Freezone 4.5 LABCONCO lyophilizer (LABCONCO Corporation, USA), 
pre-cooled at -50 ºC maintaining the lyophilization process pressure within the range of 33x10-3 to 65x10-3 
mbar for 24 h. The amount of CBZ in the suspensions after 1, 7, 14, 21, 28, 35 and 90 days post-
reconstituting the lyophilized powder were measured as described in Section 2.3. The soluble CBZ present 
in the control of free drug was used to set the 100%, and all sample data was adjusted to this value. 
 
2.5. Fourier transform infrared spectroscopy (FTIR) 
To study the D-CBZ interaction and the structural changes in the complexes respect to free dendrimers, 
FTIR spectroscopy was used. FTIR spectra of lyophilized PBS, CBZ, DG4.0, DG4.5, DG4.0-CBZ, and 
DG4.5-CBZ were measured using an FTIR Nicolet 8700 spectrometer (Thermo Fisher Scientific, USA). 
Powders were characterized placing into the attachment plate to measure attenuated total reflectance 
(ATR). After 64 scans in the range of 400 cm-1 to 4000 cm-1, the spectrum was obtained with a resolution of 
2 cm-1.  
 
2.6. In vitro drug release studies 
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In vitro release of CBZ from D-CBZ complexes was studied against buffer solutions at different pH (2.2, 7.4 
and 12.6) by using a micro-dialysis Eppendorf tube diffusion technique in which the top internal flap-cover 
of a 0.5 mL Eppendorf tube is replaced with a dialysis membrane (MW cut-off: 12000 from Sigma-Aldrich-
Merck, Argentina). This technique was developed ad hoc to overcome micro-quantities of the released drug 
(Igartúa et al., 2015). D-CBZ complexes or free drug were sealed into the micro-dialysis Eppendorf tube 
and incubated in the different buffers under continuous stirring. The CBZ release experimental design 
consisted of collecting aliquots at pre-determined time intervals (1, 2, 3, 4, 5, 6, 7, 9, 24 and 28 h) from the 
incubation medium. Each aliquot withdrawn was replaced afterward by an equal volume of fresh medium to 
maintain the volume constant during the experiment. The assay was repeated six times, and the amount of 
released CBZ was determined by absorbance at 284 nm, as described in Section 2.3.  
 
2.7. Ex vivo toxicity: Hemolysis assay and human red blood cells morphological changes 
The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved 
by the Ethics Committee of National University of Quilmes (Buenos Aires, Argentina; ethics CE-UNQ No 
2/2014). The participant (healthy donor) provided a written informed consent to the experimental protocol 
before her/his study-participation. 
Hemolysis of human red blood cells incubated with CBZ and D-CBZ complexes was assayed as previously 
described by Prieto et al. (2011) and Temprana et al. (2017) (María Jimena Prieto et al., 2011; Temprana 
et al., 2017). Briefly, freshly-prepared human red blood cells from a healthy donor were incubated at 37 °C 
with CBZ (in the range 0.3 – 30 µM), dendrimers (in the range 0.012 – 1.2 µM), D-CBZ complexes (in the 
range 0.012– 1.2 µM of D and 0.3 – 30 µM of CBZ), or PBS (10 mM, pH=7.4) as a negative control. After a 
4- or 24-h incubation, samples were centrifuged at 2000xg for 10 min, and supernatant absorbance was 
measured at 414 nm with a UV-Vis NanoDrop1000 spectrophotometer. Hemolysis was expressed as a 
percentage of the hemoglobin release induced by SDS 2% w/v set as 100% hemolysis. Additionally, 
morphological changes in red blood cells upon incubations were determined by optical microscopy. Briefly, 
after incubation, cells were mounted on a slip, stained with Giemsa for 20 min and observed with a Leica 
DMI 6000 B (Leica Microsystems, USA) microscope. 
 
2.8. In vitro toxicity: Cytotoxicity in N2a cell culture  
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2.8.1. Cell culture and treatment 
To study the influence of the proposed delivery systems on cell culture and analyze possible cytotoxic 
effects, we used the N2a cell line, a fast-growing mouse neuroblastoma cell line that has been widely used 
to study neuronal differentiation, neurite growth, synaptogenesis and signaling pathway. Also, N2a cells 
have been used to study neurotoxicity, Alzheimer's disease and asymmetric division of mammalian cell 
lines (He et al., 2017; Yang et al., 2014). Cytotoxicity upon treatment with CBZ, D or D-CBZ was measured 
by colorimetric methods as crystal violet (CV) staining, MTT assay, and neutral red (NR) uptake. The cells 
were seeded at a cell density of 7×103 cells/well in a 96-well flat bottom microplate and grown at 37 °C in 
MEM supplemented with 10% FBS and a 10% antibiotic-antimycotic solution in a humidity chamber with a 
5% CO2 atmosphere. After 24 h, the medium was replaced with 100 µL of 10-fold-serial dilutions (prepared 
in culture media) of CBZ (in the range 3x10-3 – 30 µM), dendrimers (in the range 0.12x10-3 – 1.2 µM), or D-
CBZ complexes (in the range 0.12x10-3 – 1.2 µM of D and 3×10-3 – 30 µM of CBZ). After 4 or 24 h of 
incubation, solutions were removed and replaced by the different reagent solutions according to the 
implemented method. For each assay, eight technical replicates and three biological replicates were used 
for each dilution (n=24).  
 
2.8.2. Crystal violet assay 
As adherent cells detach from cell culture plates during cell death, determination of attached cells can be 
used for the indirect quantification of cell death. A straightforward method to detect attached cells involves 
the crystal violet (CV) dye staining as the colorant binds to proteins and DNA (Kueng et al., 1989). The CV 
assay is based on the protocol described by Gillies et al. (1983) with modifications from Gasparri et al. 
(2011) (Gasparri et al., 2011; Gillies et al., 1986). Following cell exposure of 4 or 24 h to CBZ, D or D-CBZ, 
the solutions were removed and replaced by 100 µL of CV solution at a final concentration of 0.1% w/v in a 
1:4 methanol:water mixture. After 5 min of incubation in a humidity chamber, the CV solution was removed, 
and the insoluble crystals were dissolved in 100 µL of acetic acid 30% v/v. Absorbance at 530 nm was 
measured using a Cytation5 microplate reader (BioTek Instruments, USA), and is proportional to attached 
living cells. The absorbance obtained from cells incubated only with medium was used to set the 100% cell 
viability, and sample data was adjusted to this value. 
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2.8.3. MTT assay 
MTT is a water-soluble tetrazolium salt, which is converted to an insoluble purple formazan product by the 
succinate dehydrogenase enzyme within the cell mitochondria. The formazan product is impermeable to 
the cell membranes, and therefore it accumulates inside healthy cells (Fotakis & Timbrell, 2006). The MTT 
assay is based on the protocol described for the first time by Mosmann (1983) (Mosmann, 1983). Briefly, 
after 4 or 24 h of incubation with CBZ, D or D-CBZ, solutions were removed and replaced by 100 µL of 
MTT at a final concentration of 0.5 mg/mL. After 2 h of incubation, the MTT solution was removed, and the 
insoluble formazan crystals were dissolved in 100 µL of DMSO; absorbance at 570 nm was measured by 
using a Cytation5 microplate reader. Cells incubated only with medium were used to set the 100% 
metabolic activity, and sample data was adjusted to this value. 
 
2.8.4. Neutral red uptake 
Living cells take up the neutral red (NR) dye, which concentrates within the lysosomes of living cells 
(Fotakis & Timbrell, 2006). The NR assay is based on the protocol described by Borenfreund and Puerner 
(1984) (Borenfreund & Puerner, 1985). Briefly, following exposure of 4 or 24 h to CBZ, D or D-CBZ, the 
solutions were removed, and replaced by 100 µL of NR solution at a final concentration of 50 µg/mL in 
serum-free medium. After 2 h of incubation, the NR solution was removed and cells were incubated with 
100 µL of 1% formaldehyde – 1% sodium carbonate mixture, to remove unincorporated dye and 
simultaneously promote adhesion of the cells to the substratum. The formaldehyde solution was removed, 
and cells were washed with 100 µL of saline solution (NaCl 0.9% w/v). Then, 100 µL of a mixture of 1% 
acetic acid – 50% ethanol was added to each well followed by gentle shaking for 10 min so that complete 
extract of NR was achieved. The absorbance at 540 nm was measured by using a Cytation5 microplate 
reader. Cells incubated only with medium were used to set the 100% NR uptake, and sample data was 
adjusted to this value. 
 
2.9. In vivo biocompatibility: Zebrafish larvae 
2.9.1. Animals 
Adult zebrafish (Danio rerio) were maintained at 28.0 ± 1.0 °C in aquaria with a 14 h light − 10 h dark cycle, 
as described previously (Feas et al., 2017; Igartúa et al., 2015). Fishes were fed with dry flakes (TetraMin 
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PRO®) three times a day and nauplius larvae of Artemia once a day. The water in the aquarium was 
aerated and maintained at pH 7.0 - 8.0. In this study, embryos refer to zebrafish before hatching (0-3 day 
post-fecundation - dpf), while larvae refer to post-hatching animals (over 3 dpf) (Figure S3). Embryos were 
obtained from natural mating and were reared in E3 medium (NaCl 5 mM, KCl 0.17 mM, CaCl2 0.33 mM 
and MgSO4 0.33 mM in deionized water and 50 ppb methylene blue as a fungicide). Selected fertilized 
eggs in good condition were used for further treatment. The characteristics of the eggs were determined 
with a Nikon SMZ800 stereomicroscope (Nikon, USA.  
 
2.9.2. Compliance with ethical standards 
All zebrafish procedures were performed in strict accordance with the National Institute of Health guidelines 
for animal care and maintenance. The study protocols were approved by the Institutional Animal Care 
Committee of the National University of Quilmes (CE-UNQ 2/2014) (Buenos Aires, Argentina) and 
Institutional Committee for the Care and Use of Laboratory Animals (CICUAL) (CICUAL-UNQ 013-15 and 
014-15). 
 
2.9.3. Treatment 
For the treatment, three non-hatched zebrafish embryos at 1 dpf were placed in each well of a 96-well plate 
containing E3 medium and incubated for additional 4 days at 28 °C. At 5 dpf, the medium was replaced by 
250 µL of 10-fold-serial dilutions prepared in the E3 medium of CBZ (0.3-30 µM) or D-CBZ complexes 
(0.012-1.2 µM D and 0.3-30 µM CBZ). 
 
2.9.4. Viability 
Viability was studied at 1, 4, 24 and 48 hours post-incubation (hpi) with a stereomicroscope. It was 
considered that the larvae were dead when no heartbeat was observed. Viability was expressed as a 
percentage of the live larvae respect to the total of larvae per treatment (n=72).  
 
2.9.5. Neurotoxicity 
The spontaneous movement was studied in a multichannel ADC system (WMicrotracker, Designplus SRL, 
Argentina) as previously described in Igartúa et al. (2015) (Igartúa et al., 2015). Activity events were 
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recorded for 15 min at 1, 4, 24 and 48 hpi, at room temperature. The spontaneous movement was 
expressed as percentage respect to the movement in the non-treated larvae control. Changes in 
spontaneous locomotor activity events could reflect the neurotoxicity of the different treatments (Maria 
Jimena Prieto et al., 2012; Selderslaghs et al., 2013), as well as a morphological or lethal effect. For each 
assay, eight technical replicates and three biological replicates were used for each dilution (n=24). 
 
2.9.6. Cardiotoxicity 
The heart rate of zebrafish was assessed at 48 hpi (7 dpf). Control and experimental zebrafish larvae were 
individually transferred to a slide with sodium carboxymethylcellulose and placed under a trinocular 
stereomicroscope. The heart rate was determined by counting the number of beats every 15 s and 
expressed as beats per minute (bpm). Experiments were performed three times on eight larvae per group 
(n=24). The difference between the heart rates of control and treated larvae was regarded as cardiotoxicity 
(Berghmans et al., 2008).  
 
2.9.7. Morphological Changes 
The larvae were photographed after 48 hpi (7 dpf) to determine morphological changes. Several 
morphological alterations as the bent spine, jaw malformation, opaque head region, small head, opaque 
liver, opaque yolk sac, yolk not depleted, uninflated swim bladder, edema and tail malformation were 
observed. Fish were scored based on the degree of morphological anomalies [0=no visible toxic effects; 
1=minor, one to two morphological anomalies; 2=moderate, three to four effects; 3=severe, more than four 
minor toxic effects; and 4=dead] (Adaptation from (Yang et al., 2014)). The mean toxicity score for each 
treatment was determined by the score of individual larvae. Experiments were performed in triplicate on 
eight larvae per group for each dilution (n=24). 
 
2.10. Statistical Analysis 
Results are expressed as the mean ± standard deviation (SD). Statistical analysis was performed using 
Graph Pad Prism v6.0 software. ONE-WAY ANOVA test followed by Dunnett´s multiple comparisons post-
test or by TWO-WAY ANOVA test followed by Dunnett´s multiple comparisons post-tests were used 
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depending on the obtained data. The different statistical analyses used are detailed within the figures´ 
captions. Differences were considered to be significant only when p<0.05. 
 
 
3. Results and discussion 
 
3.1. CBZ complexation to obtain DG4.0-CBZ and DG4.5-CBZ complexes 
Dendrimers may increase the solubility and stability of bioactive compounds, and protect them from the 
biological environment. Solubilization of drugs mediated by dendrimers depends on the type, generation, 
size, core and functional groups of the dendrimer (Jain et al., 2010) and also depends on pH, temperature, 
and hydrophobic or electrostatic interaction affinity between the drug and the dendrimer (Kolhe et al., 
2003). The PAMAM dendrimers generation 4.0 (DG4.0) and generation 4.5 (DG4.5) can encapsulate drug 
molecules into their hydrophobic pockets or anchor them on their external functional groups. The 
complexed drug would acquire the physicochemical properties of the dendrimers, which can significantly 
increase its solubility in an aqueous media and provide a controlled-release profile (D'emanuele & Attwood, 
2005). In this sense, the drug carbamazepine (CBZ) is poorly soluble in water (120 µg/mL, 500 µM, at 25 
°C), so complexation ability of different amounts of CBZ in DG4.0 and DG4.5 was studied to estimate the 
maximum number of molecules that can be incorporated into the dendrimers molecules (Figure 1). The 
studied molar ratios were 5, 10, 25, 50, 100, 150, and 200 moles of CBZ per mole of DG4.0 or DG4.5. 
When the molar ratio was higher than 10, the soluble CBZ present in D-CBZ formulations was always 
significantly higher than the CBZ present in the control of the free drug. This result confirms the interaction 
of CBZ with both DG4.0 and DG4.5. As no significant differences were observed between DG4.0 and 
DG4.5 dendrimers, we hypothesize that the drug-dendrimer interaction is through complexation inside the 
hydrophobic pockets of dendrimers, which are chemically identical and have similar size. At molar ratios 
greater than 50, the dendrimers saturation was achieved, and higher combination ratios were not 
associated with higher amounts of complexed CBZ. However, particularly at a molar ratio of 150, a 
tendency to a more considerable amount of complexed CBZ with DG4.5 was observed, so this molar ratio 
was used to confirm the complexation and to study the reproducibility of the protocol (Table 1). By 
complexing with dendrimers, the solubility of CBZ was significantly increased in aqueous media (p<0.0001) 
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by almost three times more. At this ratio, an average of 21±7 and 24±11 moles of CBZ per mole of DG4.0 
and DG4.5, respectively, were calculated.  
Figure 1. Optimization of D:CBZ molar ratio. Different amounts of CBZ were combined with a constant quantity of 
DG4.0 or DG4.5 in methanolic solution to obtain different D:CBZ molar ratios. (A) Concentration of soluble CBZ after 
complexation process. Results are shown as mean ± SD. Significant differences respect to free CBZ were analyzed 
by TWO-WAY ANOVA test followed by Dunnett´s multiple comparisons post-test (**p<0.01, ****p< 0.0001). (B) Moles 
of CBZ per mole of DG4.0 or DG4.5 obtained after the complexation process. Data are shown as mean ± SD. 
 
Table 1. D-CBZ complexation at 1:150 D:CBZ molar ratio (n=16).  
 Soluble CBZ (µM) CBZ moles per D mole 
CBZ 322.2 ± 52.72 - 
DG4.0-CBZ 834.8 ± 187.2 **** 21 ± 7 
DG4.5-CBZ 898.7 ± 279.4 **** 24 ± 11 
Results are shown as the mean ± SD. Significant differences respect to CBZ were analyzed by ONE-WAY ANOVA 
test followed by Dunnett´s multiple comparisons post-test (****p< 0.0001). No statistical difference between CBZ moles 
per D mole was observed by T-test when DG4.0-CBZ or DG4.5-CBZ was compared.  
 
3.2. DG4.0-CBZ and DG4.5-CBZ stability and resistance to lyophilization 
The stability of the DG4.0-CBZ and DG4.5-CBZ complexes was evaluated at various conditions of 
temperature (4, 25 and 37 °C) keeping in the dark up to 90 days, and after lyophilization process, as can be 
seen in Figure 2. The formulations were found to be more stable at 37 °C as concluded by observing the 
physical appearance and by quantifying the soluble CBZ, which were significantly higher in DG4.0-CBZ and 
DG4.5-CBZ respect to free CBZ during the analyzed period of 90 days post-complexation (p<0.0001). The 
formulations were found to be stable at 25 °C only for seven days post-complexation and were non-stable 
at 4 °C. The release and crystallization of non-soluble CBZ were minimum at 37 °C and maximum at 4 °C. 
The observed results may be due to the shrinking of the dendrimer structure, which would lead to a 
decrease in the cavity entrapping the drug molecules, as was previously described (Bhadra et al., 2003). 
Furthermore, as far as we know, the resistance to lyophilization was not tested for drug complexed in 
DG4.0 and DG4.5. We observed that the formulations were stable after the lyophilization process without 
additives. In all of the formulations, the concentration of CBZ was reduced by a ~25%, but the DG4.0-CBZ 
and DG4.5-CBZ complexes remained stable at 25 °C until 60 days post-lyophilization. The increase in the 
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stability of lyophilized respect to non-lyophilized complexes at 25 °C could be because during the 
lyophilization process the drug-dendrimer interactions are maximized. 
 
Figure 2. Stability of D-CBZ complexes during storage and resistance to the lyophilization process. The time 
stability of free or complexed CBZ was studied after storage at 4, 25 or 37 °C, and after lyophilization.  (A) Percentage 
of CBZ (respect to initial concentration) at different times after complexation and storage at 4, 25 or 37 °C. (B) 
Concentration of CBZ before and after the lyophilization process. (C) Percentage of CBZ (respect to initial 
concentration) at different times after lyophilization and storage at 25 °C. (A-C) In all of the cases, results are shown 
as the mean ± SD. Significant differences respect to CBZ were analyzed by TWO-WAY ANOVA test followed by 
Dunnett´s multiple comparisons post-test (*p<0.05; **p<0.01; ***p<0.001; ****p< 0.0001) (Table S1).  
 
3.3. D-CBZ interaction studied by Fourier transform infrared spectroscopy (FTIR) and in vitro 
release  
As both DG4.0 and DG4.5 dendrimers encapsulated a similar amount of CBZ and presented similar profiles 
of stability over the time, we hypothesize that the drug-dendrimer interaction occurs into the hydrophobic 
pockets. These are chemically identical in both dendrimers whereas the terminal groups are different (–
NH3
+ for DG4.0 and –COO- for DG4.5 at physiological pH). To confirm this hypothesis, the interaction 
between CBZ and dendrimers was studied using FTIR and in vitro release studies. 
Infrared spectroscopy is a well-established nondestructive method for highly sensitive and selective 
concentration determination and identification of chemical species. FTIR works by exposing the sample to 
infrared radiation, and the infrared region of the spectrum is absorbed by the sample, so that each sample 
would have a characteristic set of absorption bands. The specific absorption of the substance in the 
“fingerprint” region enables the recognition of various chemical species and even of the structural isomers. 
FTIR spectrum of solid CBZ (Figure 3A) showed all the specific absorption bands of the drug (Milović et al., 
2012; Wu et al., 2011), including the N-H stretching band at 3460 cm-1, the –CO-R- vibration at 1670 cm-1, 
and the –C=C-, -C=O and N-H deformation vibrations at 1590 cm-1. FTIR spectra of lyophilized PBS 
(Figure 3B and C) was included as an internal control of our assay because the D-CBZ formulations were 
dissolved in this buffer before lyophilization and the buffer´s salts would remain in solid formulations. In this 
control, it was found that the absorption bands at 528, 548, 668, 861, 949, 1074, 1163, 2341 and 2359 cm-1 
correspond to the vibrations of phosphate groups of buffer´s salts.  
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FTIR spectrum of DG4.0 (Figure 3B) showed the –CH and –NH stretching vibrations of the dendrimer core 
at 2917 y 2849 cm-1; the –NH deformation vibration of the terminal groups at 1651 cm-1; and the C-C 
stretching bonds inside the core at 1557 cm-1 (Kolhe et al., 2003; Popescu et al., 2006; Prajapati et al., 
2009; M. Prieto et al., 2006). In the FTIR spectrum of DG4.0-CBZ, the disappearance of the absorption 
bands at 2917 and 2849 cm-1 and the displacement of another band from 1651 to 1692 cm-1 were 
observed. Since the first two signals correspond to internal groups of DG4.0 and the third to the terminal 
amine groups, CBZ molecules could be interacting both with the hydrophobic pockets of the DG4.0 and 
with their terminal amine groups. 
On the other hand, FTIR spectrum of DG4.5 (Figure 3C) showed the –NH flexion vibration of amides of 
dendrimer core at 3299 cm-1 and at 1642 cm-1; the –CH and –NH stretching vibrations of the dendrimer 
core at 2915 y 2849 cm-1; the -C=O stretching vibration of –COOH terminal groups at 1730 cm-1; and the –
COO symmetric vibration of terminal group at 1393 cm-1 (M. Prieto et al., 2006; Maria Jimena Prieto et al., 
2014). In the FTIR spectrum of DG4.5-CBZ, the disappearance of the absorption bands at 2915, 2849 and 
1730 cm-1 and the displacement of the bands to 3332 and 1652 cm-1 were observed. As these signals 
correspond to the internal and terminal groups of the DG4.5, the CBZ molecules could be interacting both 
with the hydrophobic pockets of the DG4.5 and with their terminal carboxylic groups. 
It is important to remember that in the D-CBZ formulations obtained from the complexation protocol there is 
the free CBZ (up to the limit of saturation) and the CBZ complexed in the dendrimers (drug solubilized by 
complexation into the hydrophobic pockets of the dendrimers). When these D-CBZ formulations are 
lyophilized, the interactions between the CBZ (both free and complexed) and the dendrimers are 
maximized, due to the evaporation of the solvent.  
As all the absorption bands corresponding to the groups of the hydrophobic pockets change in the D-CBZ 
formulations concerning the free dendrimers, we can confirm our hypothesis that the drug interacts with the 
hydrophobic pockets of both nanocarriers. As there are also some changes in the signals corresponding to 
the terminal groups of both DG4.0 and DG4.5, it is not possible to rule out that the CBZ interaction with 
them due to the proximity during the lyophilization process. 
 
Figure 3. Interaction between CBZ and DG4.0 or DG4.5 by FTIR analysis. (A) FTIR spectrum of CBZ powder; (B) 
FTIR spectra of lyophilized DG4.0, DG4.0-CBZ, and PBS control; (C) FTIR spectra of lyophilized DG4.5, DG4.5-CBZ, 
and PBS control. (B-C) Shifts or disappearance of the maximums observed in the spectrum of dendrimers respect to 
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D-CBZ complexes are included into the study because the complexes and dendrimers were lyophilized from buffer 
suspension, and phosphate salts have a strong signal in FTIR.   
 
The strength and stability of the drug-dendrimer complex were also studied using in vitro release assays of 
CBZ from DG4.0-CBZ and DG4.5-CBZ against PBS at physiological pH 7.4 (Figure 4) and extreme pHs of 
2.2 and 12.6 (Figure S4). CBZ is a molecule with hydrophobic rings and a polar region due to the presence 
of an amide group. Under non-catalyzing conditions and at extreme basic pHs, CBZ can form negatively 
charged amide (pKa of amide group 13.9) (Röhricht et al., 2009). In all the pHs used in this work, the CBZ 
can be found as an uncharged molecule. Moreover, DG4.0 present primary amino groups as terminal ends 
with pKa 8-10 and internal tertiary amines with pKa 4-6; while DG4.5 present carboxylic acids as terminal 
ends with pKa 4-5 and internal tertiary amines with pKa 3-6 (Devarakonda et al., 2007; Maiti et al., 2005; 
Maiti et al., 2004). Therefore, both dendrimers are macromolecules whose degree of ionization and the 
conformational state will depend on the pH. 
At acid pH (2.2) (Figure S4 A) the internal tertiary amines of both dendrimers would be protonated; this 
excessive positive charge would lead to an extended conformation, preventing the formation of 
hydrophobic pockets inside the dendrimers. Moreover, it was previously reported that at pH<4.0, the 
dendrimer size increased almost 30-40% (Maiti et al., 2005; Maiti et al., 2004). These structural changes 
lead to the complete release of the CBZ from D-CBZ complexes.  
At basic pH (12.6) (Figure S4 B) the internal tertiary amines of both dendrimers would be deprotonated, 
and the end groups -NH2 of the DG4.0 would also be deprotonated; this absence of charges would give rise 
to a compact globular conformation (Maria Jimena Prieto et al., 2013). However, Maiti et al. (2005) found 
that at pH>12.0 and in the presence of a solvent such as water, the size of the dendrimer was increased by 
almost 10-15% (Maiti et al., 2005). The same conformational change can be expected for the DG4.5 
considering that their terminal groups -COO- would be negatively charged. Under these conditions, CBZ 
was completely released from both DG4.0-CBZ and DG4.5-CBZ complexes. 
At physiological pH (7.4) (Figure 4) the internal tertiary amines of both dendrimers would be deprotonated 
forming hydrophobic pockets, while the end groups would have positive charges -NH3
+ for DG4.0 and 
negative charges -COO- for DG4.5. As it was previously described, at neutral pH, there was no significant 
change in the dendrimer size (Maiti et al., 2005; Maiti et al., 2004). Under these conditions, the CBZ 
molecules could interact hydrophobically or by hydrogen bonding with the core of the dendrimers, which 
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results in a controlled release over time. After 2 h of dialysis, the free CBZ was released by 70%, while the 
D-CBZ by 45% (p<0.001). Subsequently, after 24 h of dialysis, the free CBZ was completely released 
(100%), while the D-CBZ complexes still retained 40% of the drug (p<0.0001). Consistent with our results, 
the drug retention capacity of both dendrimers under physiological conditions had previously been 
observed for the drug risperidone (Maria Jimena Prieto et al., 2014; María Jimena Prieto et al., 2011) and 
ibuprofen (Kolhe et al., 2003). Moreover, it was also found that the interaction between dendrimers and 
drugs is strongly dependent on pH (Beezer et al., 2003; Devarakonda et al., 2007). 
 
Figure 4. In vitro release of CBZ from D-CBZ complexes in physiological pH 7.4. The in vitro release of CBZ from 
D-CBZ complexes was studied against buffer solution with pH 7.4 by using a micro-dialysis Eppendorf tube diffusion 
technique developed ad hoc. Results are shown as mean ± SD. Significant differences respect to CBZ were analyzed 
by TWO-WAY ANOVA test followed by Dunnett´s multiple comparisons post-test (*p<0.05; **p<0.01; ***p<0.001; 
****p< 0.0001) (Table S2).  
 
3.4. Ex vivo toxicity: Hemolysis assay and human red blood cells morphological changes 
Red blood cell hemolysis and morphological changes study are simple methods widely used to analyze 
polymer-membrane interaction and ex vivo toxicity (Duncan & Izzo, 2005; Temprana et al., 2017). Despite 
hemolysis caused by cationic and anionic dendrimers is reported to be generation- and concentration-
dependent, non-hemolysis is found at low dendrimer concentration (<1 mg/mL) (Asthana et al., 2005; 
Bhadra et al., 2003; Malik et al., 2000; María Jimena Prieto et al., 2011). However, it is of importance to test 
the hemolytic effect of the complexes as it has been reported that CBZ can induce hemolytic anemia 
(Sobotka et al., 1990; Stroink et al., 1984; Yamamoto et al., 2007). In this work, we evaluated the hemolytic 
effects (Figure 5) and possible morphological changes (Figure S5) after 4- and 24-h human red blood cells 
incubation with free CBZ, dendrimers and D-CBZ complexes. No significant hemolysis or morphological 
changes were observed when compared with red blood cells incubated with isotonic PBS buffer (negative 
control) at any incubation time.  
 
Figure 5. Ex vivo toxicity studied by hemolysis in human red blood cells. Hemolysis after 4- or 24-h treatments 
with CBZ, dendrimers or D-CBZ complexes. Hemolysis is expressed as a percentage of the hemoglobin release 
induced by the SDS positive control (100% hemolysis). Results are shown as mean ± SD. Significant differences 
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respect to PBS negative control was performed by TWO-WAY ANOVA test followed by Dunnett´s multiple 
comparisons post-test. There were no significant differences for any of the formulations at the tested concentrations.  
 
3.5. In vitro toxicity: Cytotoxicity in N2a cell culture 
Regardless of the extensive pharmaceutical and biomedical applications of dendrimers, it is reported that 
dendrimer cytotoxicity might restrict their use as drug delivery systems (Jain et al., 2010; María Jimena 
Prieto et al., 2011). Thus, it is imperative to evaluate the cytotoxicity of dendrimers themselves and the 
obtained complexes. The cytotoxicity of the dendrimers is dependent on the kind of the core, but mainly on 
the nature of its surface groups (Duncan & Izzo, 2005). Also, the cytotoxicity is found to be concentration- 
and time-dependent in different cell lines (Duncan & Izzo, 2005; Jain et al., 2010). DG4.0 are cationic 
dendrimers at physiological pH that can cause more cytotoxic effects than negative dendrimers DG4.5. For 
example, on Vero and J774 cell lines, DG4.0 presented cytotoxicity at 3 μM concentration after 24 h (María 
Jimena Prieto et al., 2011) whereas DG4.5 presented no cytotoxicity up to 33 μM (M. Prieto et al., 2006). 
The observations reported are due to cationic dendrimers´ ability to interact with the negatively charged 
plasma membrane, generating destabilization and cell membrane nanoholes, thus resulting in cell lysis 
(Jain et al., 2010). 
While most chemical compounds cause cellular damage through interaction with specific biomolecules, 
nanoparticles can cause toxicity through a combination of different mechanisms such as inducing ROS, 
genotoxicity, morphological modifications and immunological effects at the same time (Joris et al., 2013). 
So, it is important to study the effect of dendrimers and complexes in cell culture by several methods 
simultaneously (Fotakis & Timbrell, 2006). In the present work, we studied the effects of CBZ, dendrimers, 
and D-CBZ complexes in N2a cell line after 4- and 24-h treatments on viability by the crystal violet (CV) 
staining; on cellular metabolic activity by the MTT assay; and on lysosomal activity by the neutral red (NR) 
uptake (Figure 6 and S6). After 4 h (Figure S6), no reduction in N2a cell viability (CV staining) or effects 
on metabolic activity (MTT assay) were observed for any of the treatments and the concentrations tested. 
However, 1.2 µM of DG4.0 caused a reduction of ~20% in the uptake of NR, which might be related to the 
toxic effect of cationic dendrimers on cells membranes, particularly in the lysosomal membrane. After 24-h 
treatments (Figure 6), results of the three assays were not in accordance, which can be explained by the 
fact that each test analyzes different parameters involved in cellular toxicity. The MTT assay is mainly 
based on the enzymatic conversion of MTT in the mitochondria, whereas the NR assay is a colorimetric 
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assay measuring the uptake of the dye by functional lysosomes, and CV staining measured the uptake of 
the dye by attached and viable cells (Fotakis & Timbrell, 2006). The CV staining revealed that 0.03 and 
0.003 μM of CBZ reduced cell viability by 40% and 30% respectively. The DG4.5-CBZ complex prevented 
this cytotoxic effect, although the DG4.0-CBZ did not. Regarding the metabolic activity studied by the MTT 
assay, none of the formulations in the evaluated concentrations produced cytotoxic effects. However, 
cytotoxicity measured as reduction of NR uptake was observed at the higher concentration of free 
dendrimers and D-CBZ complexes. This effect on lysosomes produced by dendrimers was previously 
described (Mukherjee et al., 2010; J. Zhang et al., 2016). As expected, the toxic effect was more significant 
for DG4.0 than for DG4.5 and it was reflected in shorter times.   
In conclusion, the use of different concentrations, treatment-times, and methods to study the toxic effects in 
the N2a cells, allowed to demonstrate that the DG4.5-CBZ complexes presented reduced toxicity 
concerning the other formulation (DG4.0-CBZ) or the free CBZ.  
 
Figure 6. In vitro toxicity studied in N2a cell culture by colorimetric methods.  Cytotoxicity measured as viability 
by the crystal violet (CV) staining, metabolic activity by the MTT assay, and lysosomal activity by the neutral red (NR) 
uptake at 24 hours post-incubation (hpi) with CBZ, dendrimers or D-CBZ complexes. All data are expressed as the 
percentage respect to non-treated cells control, which was considered as 100% of viability, 100% metabolic activity or 
100% neutral red uptake. Results are shown as the mean ± SD. Statistics were performed by ONE-WAY ANOVA test 
followed by Dunnett´s multiple comparisons post-test. Significantly different respect to the control (**p<0.01; 
***p<0.001; ****p< 0.0001).  
 
3.6. In vivo biocompatibility: Zebrafish larvae 
While the term “toxicity” is referring to the non-specific and undesired effects of a drug or nanoparticle, the 
term “biocompatibility” is wider and could be referring to the ability to be in contact with a living system 
without producing an adverse effect (Vert et al., 2012). Hence, it is critical to study the effect of the obtained 
complexes in a living organism. Particularly, in this work, we chose to work with Zebrafish (Danio rerio) 
which is an animal model that offers whole-animal information, which cannot be obtained from in vitro 
studies. Furthermore, we used zebrafish larvae as a rapid, high-throughput, cost-effective model to provide 
a more comprehensive and predictive screening of biocompatibility of the free CBZ and D-CBZ complexes. 
The effect on the viability (Figure 7A), spontaneous swimming activity (Figure 7B), morphological 
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development (Figure 7C), and heart rate (Figure 7D) of zebrafish larvae after treatment with CBZ or D-
CBZ were studied. Neither free CBZ nor DG4.5-CBZ complexes produced mortality, malformations or 
changes in heart rate or spontaneous movement at the evaluated concentrations. On the other hand, when 
high concentrations of the DG4.0-CBZ complex (30 µM CBZ encapsulated in 1.2 µM of DG4.0) were 
administered, only 68 and 57% of viability was observed after 4- and 24-h treatments, respectively. At 48-h 
treatments, the viability remained at 57%. In addition, at this dose, significant morphological changes were 
also observed (Figure 8) such as uninflated swim bladder, opaque yolk sac, and yolk not depleted. The 
tendency in the reduction of the movement and the heartbeat are directly related to the lethal effect of the 
DG4.0 and not with neurological or cardiological effects indeed. In non-lethal doses, complexes did not 
cause any other effects. Results are consistent with those obtained by Calienni et al. (2017), in which free 
DG4.0 were lethal for zebrafish larvae in concentrations higher than 0.5 µM (Calienni et al., 2017).  
 
Figure 7. In vivo toxicity studied in zebrafish larvae. (A) Viability of zebrafish larvae at 7 dpf after a 48-h treatment 
with CBZ or D-CBZ complexes. Viability is expressed as the percentage of the live larvae respect to the total of larvae, 
and data are shown as mean ± SD. Statistics were performed by ONE-WAY ANOVA test followed by Dunnett´s 
multiple comparisons post-test. Significantly different respect to CBZ (***p<0.001). (B) Spontaneous movement in 
zebrafish larvae after 1-, 4-, 24- and 48-h treatment with CBZ or D-CBZ complexes. Spontaneous movement is 
expressed as the percentage respect to movement in the non-treated larvae control, and results are shown as mean ± 
SD. None significant differences respect to CBZ was found after analysis by TWO-WAY ANOVA test followed by 
Dunnett´s multiple comparisons post-test. (C) Morphological changes scored based on the degree of anomalies of 
zebrafish larvae at 7 dpf after 48-h treatment with CBZ or D-CBZ complexes. Statistics were performed by ONE-WAY 
ANOVA test followed by Dunnett´s multiple comparisons post-test. Significantly different respect to CBZ 
(****p<0.0001). (D) Heart rate of zebrafish larvae at 7 dpf after 48-h treatment with CBZ or D-CBZ. Heart rate is 
expressed as the percentage of heartbeat in treated larvae respect to the heartbeat in the non-treated larvae control, 
and data are shown as mean ± SD. Significant differences respect to CBZ was performed by ONE-WAY ANOVA test 
followed by Dunnett´s multiple comparisons post-test (****p<0.0001). 
 
Figure 8. In vivo morphological changes studied in zebrafish larvae. Representative photographs of live 7-dpf 
zebrafish larvae after a 48-h treatment with 30 µM of CBZ or D-CBZ complexes. Significant morphological changes 
are indicated with arrows.  
 
  
22 
 
Taking into account these results to those previously obtained ex vivo and in vitro, we can conclude that the 
DG4.5-CBZ complexes were non-toxic and biocompatible in the concentrations tested. These complexes 
are presented as an alternative to the delivery of CBZ, a water-insoluble drug which has been approved for 
the treatment of epilepsy and shows the potential for the development of new therapies against 
neurodegenerative diseases. 
 
4. Conclusions and perspectives  
A stable drug delivery system based on the PAMAM dendrimer generation 4.5 capable of efficiently 
complex the antiepileptic drug CBZ has been developed. Not only the drug solubility was increased by 
using DG4.5 but also a controlled release profile was achieved observing that a 40% of the CBZ was 
retained after 28-h dialysis. Moreover, drug cytotoxicity was reduced when CBZ was complexed within this 
dendrimer. Furthermore, the complex DG4.5-CBZ did not have a hemolytic activity or induced 
morphological changes in human red blood cells and presented high in vivo biocompatibility as no 
neurotoxicity, cardiotoxicity or malformations were observed in the zebrafish model. 
Considering all mentioned above, the DG4.5-CBZ could be incorporated into clinical trials, leading to an 
improvement of the already established treatment of epilepsy. Moreover, this work could be considered a 
starting point to study new treatments for other neurodegenerative diseases. In line with this idea, further 
experiments will be carried out to explore the ability of the DG4.5-CBZ complexes in reducing abnormal 
aggregation of β-amyloid proteins in cell culture and mammalian models. Finally, our work highlights the 
advantage of using negatively charged PAMAM dendrimers when designing stable and non-toxic drug 
delivery systems. 
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Figure Legends 
 
Figure 1. Optimization of D:CBZ molar ratio. Different amounts of CBZ were combined with a constant quantity of 
DG4.0 or DG4.5 in methanolic solution to obtain different D:CBZ molar ratios. (A) Concentration of soluble CBZ after 
complexation process. Results are shown as mean ± SD. Significant differences respect to free CBZ were analyzed 
by TWO-WAY ANOVA test followed by Dunnett´s multiple comparisons post-test (**p<0.01, ****p< 0.0001). (B) Moles 
of CBZ per mole of DG4.0 or DG4.5 obtained after the complexation process. Data are shown as mean ± SD. 
 
Figure 2. Stability of D-CBZ complexes during storage and resistance to the lyophilization process. The time 
stability of free or complexed CBZ was studied after storage at 4, 25 or 37 °C, and after lyophilization.  (A) Percentage 
of CBZ (respect to initial concentration) at different times after complexation and storage at 4, 25 or 37 °C. (B) 
Concentration of CBZ before and after the lyophilization process. (C) Percentage of CBZ (respect to initial 
concentration) at different times after lyophilization and storage at 25 °C. (A-C) In all of the cases, results are shown 
as the mean ± SD. Significant differences respect to CBZ were analyzed by TWO-WAY ANOVA test followed by 
Dunnett´s multiple comparisons post-test (*p<0.05; **p<0.01; ***p<0.001; ****p< 0.0001) (Table S1).  
 
Figure 3. Interaction between CBZ and DG4.0 or DG4.5 by FTIR analysis. (A) FTIR spectrum of CBZ powder; (B) 
FTIR spectra of lyophilized DG4.0, DG4.0-CBZ, and PBS control; (C) FTIR spectra of lyophilized DG4.5, DG4.5-CBZ, 
and PBS control. (B-C) Shifts or disappearance of the maximums observed in the spectrum of dendrimers respect to 
D-CBZ complexes are included into the study because the complexes and dendrimers were lyophilized from buffer 
suspension, and phosphate salts have a strong signal in FTIR.   
 
Figure 4. In vitro release of CBZ from D-CBZ complexes in physiological pH 7.4. The in vitro release of CBZ from 
D-CBZ complexes was studied against buffer solution with pH 7.4 by using a micro-dialysis Eppendorf tube diffusion 
technique developed ad hoc. Results are shown as mean ± SD. Significant differences respect to CBZ were analyzed 
by TWO-WAY ANOVA test followed by Dunnett´s multiple comparisons post-test (*p<0.05; **p<0.01; ***p<0.001; 
****p< 0.0001) (Table S2).  
 
Figure 5. Ex vivo toxicity studied by hemolysis in human red blood cells. Hemolysis after 4- or 24-h treatments 
with CBZ, dendrimers or D-CBZ complexes. Hemolysis is expressed as a percentage of the hemoglobin release 
induced by the SDS positive control (100% hemolysis). Results are shown as mean ± SD. Significant differences 
respect to PBS negative control was performed by TWO-WAY ANOVA test followed by Dunnett´s multiple 
comparisons post-test. There were no significant differences for any of the formulations at the tested concentrations.  
 
Figure 6. In vitro toxicity studied in N2a cell culture by colorimetric methods.  Cytotoxicity measured as viability 
by the crystal violet (CV) staining, metabolic activity by the MTT assay, and lysosomal activity by the neutral red (NR) 
uptake at 24 hours post-incubation (hpi) with CBZ, dendrimers or D-CBZ complexes. All data are expressed as the 
percentage respect to non-treated cells control, which was considered as 100% of viability, 100% metabolic activity or 
100% neutral red uptake. Results are shown as the mean ± SD. Statistics were performed by ONE-WAY ANOVA test 
followed by Dunnett´s multiple comparisons post-test. Significantly different respect to the control (**p<0.01; 
***p<0.001; ****p< 0.0001).  
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Figure 7. In vivo toxicity studied in zebrafish larvae. (A) Viability of zebrafish larvae at 7 dpf after a 48-h treatment 
with CBZ or D-CBZ complexes. Viability is expressed as the percentage of the live larvae respect to the total of larvae, 
and data are shown as mean ± SD. Statistics were performed by ONE-WAY ANOVA test followed by Dunnett´s 
multiple comparisons post-test. Significantly different respect to CBZ (***p<0.001). (B) Spontaneous movement in 
zebrafish larvae after 1-, 4-, 24- and 48-h treatment with CBZ or D-CBZ complexes. Spontaneous movement is 
expressed as the percentage respect to movement in the non-treated larvae control, and results are shown as mean ± 
SD. None significant differences respect to CBZ was found after analysis by TWO-WAY ANOVA test followed by 
Dunnett´s multiple comparisons post-test. (C) Morphological changes scored based on the degree of anomalies of 
zebrafish larvae at 7 dpf after 48-h treatment with CBZ or D-CBZ complexes. Statistics were performed by ONE-WAY 
ANOVA test followed by Dunnett´s multiple comparisons post-test. Significantly different respect to CBZ 
(****p<0.0001). (D) Heart rate of zebrafish larvae at 7 dpf after 48-h treatment with CBZ or D-CBZ. Heart rate is 
expressed as the percentage of heartbeat in treated larvae respect to the heartbeat in the non-treated larvae control, 
and data are shown as mean ± SD. Significant differences respect to CBZ was performed by ONE-WAY ANOVA test 
followed by Dunnett´s multiple comparisons post-test (****p<0.0001). 
 
Figure 8. In vivo morphological changes studied in zebrafish larvae. Representative photographs of live 7-dpf 
zebrafish larvae after a 48-h treatment with 30 µM of CBZ or D-CBZ complexes. Significant morphological changes 
are indicated with arrows. 
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Table 1. D-CBZ complexation at 1:150 D:CBZ molar ratio (n=16).  
 Soluble CBZ (µM) CBZ moles per D mole 
CBZ 322.2 ± 52.72 - 
DG4.0-CBZ 834.8 ± 187.2 **** 21 ± 7 
DG4.5-CBZ 898.7 ± 279.4 **** 24 ± 11 
Results are shown as the mean ± SD. Significant differences respect to CBZ were analyzed by ONE-WAY ANOVA 
test followed by Dunnett´s multiple comparisons post-test (****p< 0.0001). No statistical difference between CBZ moles 
per D mole was observed by T-test when DG4.0-CBZ or DG4.5-CBZ was compared.  
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